Mutant b-raf polypeptide and a use thereof in the diagnosis of cancer
CA 2471114 C · Owner: Marshall, Chris · Inventors: Wooster, Richard; Futreal, Andy; Marais, Richard Malcolm
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to mutations in B-Raf gene products. The mutations described are identified in human tumours of natural origin. These mutations are associated with cancerous phenotypes and can be used as a basis for the diagnosis of cancer, cancerous cells or a predisposition to cancer in human subjects, and the development of anti-cancer therapeutics.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 23, 2002 and granted March 20, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 23, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 23, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.